See more : Analog Devices, Inc. (ANL.DE) Income Statement Analysis – Financial Results
Complete financial analysis of BioAtla, Inc. (BCAB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioAtla, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Alexander’s, Inc. (ALX) Income Statement Analysis – Financial Results
- FLSmidth & Co. A/S (FLIDY) Income Statement Analysis – Financial Results
- Green Impact Partners Inc. (GIPIF) Income Statement Analysis – Financial Results
- Fischer Chemic Limited (FISCHER.BO) Income Statement Analysis – Financial Results
- Shanghai Industrial Development Co.,Ltd (600748.SS) Income Statement Analysis – Financial Results
BioAtla, Inc. (BCAB)
About BioAtla, Inc.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 250.00K | 429.00K | 5.20M | 10.63M |
| Cost of Revenue | 103.73M | 1.20M | 1.33M | 19.93K | 25.92K | 26.31M |
| Gross Profit | -103.73M | -1.20M | -1.08M | 409.07K | 5.17M | -15.68M |
| Gross Profit Ratio | 0.00% | 0.00% | -432.00% | 95.35% | 99.50% | -147.53% |
| Research & Development | 103.73M | 79.35M | 58.27M | 19.93M | 25.92M | 26.31M |
| General & Administrative | 25.96M | 28.79M | 38.42M | 10.60M | 7.55M | 12.56M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.96M | 28.79M | 38.42M | 10.60M | 7.55M | 12.56M |
| Other Expenses | 0.00 | 10.00K | 1.00K | -1.00K | -22.00K | -5.00K |
| Operating Expenses | 129.69M | 108.14M | 96.69M | 30.53M | 33.47M | 38.86M |
| Cost & Expenses | 129.69M | 108.14M | 96.69M | 30.53M | 33.47M | 38.86M |
| Interest Income | 6.31M | 1.65M | 350.00K | 100.00K | 128.00K | 209.00K |
| Interest Expense | 0.00 | 3.00K | 1.39M | 1.63M | 949.00K | |
| Depreciation & Amortization | 1.22M | 1.20M | 1.33M | 1.01M | 860.00K | 794.00K |
| EBITDA | -122.24M | -106.48M | -94.07M | -33.46M | -27.37M | -27.24M |
| EBITDA Ratio | 0.00% | 0.00% | -37,903.60% | -6,758.04% | -525.04% | -256.29% |
| Operating Income | -129.69M | -108.14M | -96.44M | -30.10M | -28.27M | -28.23M |
| Operating Income Ratio | 0.00% | 0.00% | -38,576.00% | -7,016.08% | -543.62% | -265.68% |
| Total Other Income/Expenses | 6.23M | 1.66M | 1.04M | -5.75M | -1.59M | -745.00K |
| Income Before Tax | -123.46M | -106.48M | -95.40M | -35.85M | -29.86M | -28.98M |
| Income Before Tax Ratio | 0.00% | 0.00% | -38,160.80% | -8,357.34% | -574.13% | -272.69% |
| Income Tax Expense | 0.00 | -1.20M | 4.00K | 1.39M | 1.55M | 204.00K |
| Net Income | -123.46M | -105.28M | -95.41M | -37.24M | -31.40M | -28.98M |
| Net Income Ratio | 0.00% | 0.00% | -38,162.40% | -8,680.89% | -603.88% | -272.69% |
| EPS | -2.58 | -2.70 | -2.76 | -1.11 | -0.93 | -1.34 |
| EPS Diluted | -2.58 | -2.70 | -2.76 | -1.11 | -0.93 | -1.34 |
| Weighted Avg Shares Out | 47.78M | 38.93M | 34.56M | 33.66M | 33.66M | 21.59M |
| Weighted Avg Shares Out (Dil) | 47.78M | 38.93M | 34.56M | 33.66M | 33.66M | 21.59M |
BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript
BioAtla, Inc. (NASDAQ:BCAB ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Eric...
BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy
BioAtla's proprietary CAB platform offers precise cancer targeting, minimizing harm to healthy cells, with promising clinical trial outcomes for its ADCs and immuno-oncology treatments. The company faces a tight cash runway until Q3 2025, raising concerns about dilution and short-term...
BioAtla: Numerous Catalysts Coming In Q4
BioAtla, Inc. has promising pipeline projects, including masked antibodies and ADCs targeting AXL and ROR2, showing early efficacy and potential for improved cancer treatments. Financially, BioAtla faces challenges with less than a year of cash, despite a licensing deal with...
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at...
Michael Burry buys 634,000 shares of this $1 penny stock
When Michael Burry, the man who famously bet against the housing market before the 2008 financial crash, makes a move, investors take notice.
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress
SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced acceptance of an abstract...
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $118.5 million, plus royalties on net sales Context anticipated...
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $118.5 million, plus royalties on net sales Context anticipated...
BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript
BioAtla, Inc. (NASDAQ:BCAB ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Dr. Jay Short - Chairman, Co-Founder and CEO Richard Waldron - Chief Financial Officer Dr. Eric Sievers...
BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today hosted a virtual R&D Day...
Source: https://incomestatements.info
Category: Stock Reports